International experts in the field of diabetes and diabetes technology met in Warsaw, Poland, for the 10th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts to facilitate new collaborations and research projects that can improve the lives of people with diabetes. The 2017 meeting comprised a comprehensive scientific program, parallel interactive workshops, and four keynote lectures.
Get full access to this article
View all access options for this article.
References
1.
HoldenSE, Jenkins-JonesS, CurrieCJ: Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: a retrospective cohort study. PLoS One, 2016; 11(5): e0153594.
2.
MarsoSP, DanielsGH, Brown-FrandsenK, et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375:311–322.
3.
MarsoSP, BainSC, ConsoliA, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016; 375:1834–1844.
4.
PfefferMA, ClaggettB, DiazR, et al.: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med, 2015; 373:2247–2257.
5.
ZinmanB, WannerC, LachinJM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373:2117–2128.
6.
KosiborodM, CavenderMA, FuAZ, et al.: Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation, 2017; 136:249–259.
7.
BeckRW, RiddlesworthT, RuedyK, et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA, 2017; 317:371–378.
8.
BergenstalR, RiddlesworthT, RuedyK, et al.: Patients with type 2 diabetes using multiple daily insulin injections have high adherence and benefit from CGM: a prospective, randomized controlled trial. Presented at: 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). February 15–18, 2017; Paris, France.
9.
GargSK, VoelmleMK, BeatsonCR, et al.: Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care, 2011; 34:574–579.
10.
GargSK, WeinzimerSA, TamborlaneWV, et al.: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
11.
BergenstalRM, GargS, WeinzimerSA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
12.
CahillGFJr., EtzwilerLD, FreinkelN: Editorial: “Control” and diabetes. N Engl J Med, 1976; 294(18):1004–1005.
13.
SipersteinMD, FosterDW, KnowlesHC, LevineR, MadisonLL, RothJ: Control of blood glucose and diabetic vascular disease. N Engl J Med, 1977; 296(18):1060–1063.
14.
ZoungasS, ChalmersJ, NealB, et al.: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med, 2014; 371:1392–1406.
15.
GaedeP, Lund-AndersenH, ParvingHH, PedersenO: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358:580–591.
16.
TriccoAC, IversNM, GrimshawJM, et al.: Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet, 2012; 379:2252–2261.
17.
GroupRS: Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ, 2017; 356:j1285.
18.
TanseyM, LaffelL, ChengJ, et al.: Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. Diabet Med, 2011; 28:1118–1122.
19.
PettusJ, EdelmanSV: Recommendations for using real-time continuous glucose monitoring (rtCGM) data for insulin adjustments in type 1 diabetes. J Diabetes Sci Technol, 2017; 11:138–147.
20.
SoupalJ, PetruzelkovaL, FlekacM, et al.: Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther, 2016; 18:532–538.
21.
BorotS, FrancS, CristanteJ, et al.: Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies. J Diabetes Sci Technol, 2014; 8:1133–1141.
22.
JahnLG, CapurroJJ, LevyBL: Comparative dose accuracy of durable and patch insulin infusion pumps. J Diabetes Sci Technol, 2013; 7:1011–1020.
23.
BowenJL, AllenderCJ: Comparative pulse accuracy study of two commercially available patch insulin infusion pumps. Eur Endocrinol, 2016; 12:79–84.
24.
ZisserH, BretonM, DassauE, et al.: Novel methodology to determine the accuracy of the OmniPod insulin pump: a key component of the artificial pancreas system. J Diabetes Sci Technol, 2011; 5:1509–1518.
25.
FrancS, DaoudiA, PochatA, et al.: Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the DIABRASPORT randomized study. Diabetes Obes Metab, 2015; 17:1150–1157.
26.
MoniotteS, OwenM, BarreaT, et al.: Outcomes of algorithm-based modifications of insulinotherapy during exercise in MDI vs insulin pump-treated children with type 1 diabetes: results from the TREAD-DIAB study. Pediatr Diabetes, 2017; doi: 10.1111/pedi.12509.
27.
International Hypoglycaemia Study Group: Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2017; 40:155–157.
28.
HempeJM, SorosAA, ChalewSA: Estimated average glucose and self-monitored mean blood glucose are discordant estimates of glycemic control. Diabetes Care, 2010; 33:1449–1451.
29.
NathanDM, KuenenJ, BorgR, et al.: Translating the A1C assay into estimated average glucose values. Diabetes Care, 2008; 31:1473–1478.
30.
KovatchevBP, FlackeF, SieberJ, BretonMD: Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose data. Diabetes Technol Ther, 2014; 16:303–309.
31.
KovatchevBP, BretonMD: Hemoglobin A1c and self-monitored average glucose: validation of the dynamical tracking eA1c algorithm in type 1 diabetes. J Diabetes Sci Technol, 2015; 10:330–335.
32.
American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care, 2013; 36:1033–1046.
33.
KokkinosP, MyersJ, KokkinosJP, et al.: Exercise capacity and mortality in black and white men. Circulation, 2008; 117:614–622.
34.
KodamaS, SaitoK, TanakaS, et al.: Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA, 2009; 301:2024–2035.
35.
LinX, ZhangX, GuoJ, et al.: Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 2015; 4:e002014.
36.
ChurchTS, ThomasDM, Tudor-LockeC, et al.: Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One, 2011; 6:e19657.
37.
ArcherE, ShookRP, ThomasDM, et al.: 45-Year trends in women's use of time and household management energy expenditure. PLoS One, 2013; 8:e56620.
38.
BarryVW, BaruthM, BeetsMW, et al.: Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis, 2014; 56:382–390.
39.
McAuleyPA, ArteroEG, SuiX, et al.: The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc, 2012; 87:443–451.
40.
LavieCJ, CahalinLP, ChaseP, et al.: Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc, 2013; 88:251–258.
41.
WenCP, WaiJP, TsaiMK, et al.: Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet, 2011; 378:1244–1253.
42.
LeeDC, PateRR, LavieCJ, et al.: Leisure-time running reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol, 2014; 64:472–481.
43.
BolinderJ, AntunaR, Geelhoed-DuijvestijnP, et al.: Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet, 2016; 388:2254–2263.
44.
HaakT, HanaireH, AjjanR, et al.: Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther, 2017; 8:55–73.
45.
VegasAJ, VeisehO, GurtlerM, et al.: Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med, 2016; 22:306–311.
46.
CafazzoJA, CasselmanM, HammingN, et al.: Design of an mHealth app for the self-management of adolescent type 1 diabetes: a pilot study. J Med Internet Res, 2012; 14:e70.
47.
BretonMD, KovatchevBP: Impact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study. J Diabetes Sci Technol, 2010; 4:562–570.
48.
BrazgRL, KlaffLJ, ParkinCG: Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers. J Diabetes Sci Technol, 2013; 7(1):144–152.
49.
BarnardKD, LloydCE, DysonPA, et al.: Kaleidoscope model of diabetes care: time for a rethink?. Diabet Med, 2014; 31:522–530.
